Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE selexipag study in pulmonary arterial hypertension
NL-OMON52455Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in right ventricular stroke volume. Started Mar 2022; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON52455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52455.